-
Notifications
You must be signed in to change notification settings - Fork 0
Expand file tree
/
Copy pathCTCC.html
More file actions
186 lines (177 loc) · 14.6 KB
/
Copy pathCTCC.html
File metadata and controls
186 lines (177 loc) · 14.6 KB
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
<!DOCTYPE HTML>
<!--
Landed by HTML5 UP
html5up.net | @ajlkn
Free for personal and commercial use under the CCA 3.0 license (html5up.net/license)
-->
<html>
<head>
<title>Nilay Vora | Portfolio</title>
<meta charset="utf-8" />
<meta name="viewport" content="width=device-width, initial-scale=1, user-scalable=no" />
<link rel="stylesheet" href="assets/css/main.css" />
<link rel="icon" href="./images/Identity.png" type="image/png"/>
<noscript><link rel="stylesheet" href="assets/css/noscript.css" /></noscript>
</head>
<body class="is-preload" style= background-color:white;>
<div id="page-wrapper">
<!-- Header -->
<header id="header">
<img src="images/Logo.png" alt="logo" />
<h1 id="logo"><a href="index.html">Nilay Vora</a></h1>
<nav id="nav">
<ul>
<li><a href="index.html">Home</a></li>
<li><a href="About.html">About Me</a></li>
<li>
<a href="#">Projects</a>
<ul>
<li><a href="#">Research</a>
<ul>
<li><a href="CTCC.html">ML Label-Free Flow Cytometry</a></li>
<li><a href="Denoising2PImages.html">DL Denoising Two-Photon Microscopy Images</a></li>
</ul>
</li>
<li><a href="#">Outreach</a>
<ul>
<li><a href="TOJC.html">Tufts Optics Journal Club</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="Experience.html">Experience</a></li>
<li><a href="mailto:nilay.vora@tufts.edu" class="button primary">Contact Me</a></li>
</ul>
</nav>
</header>
<!-- Main -->
<div id="main" class="wrapper style1">
<div class="container">
<header class="major">
<h2 style="color:black">ML-Enabled, Label-free Detection of Rare Circulating Tumor Cell Clusters (CTCCs) in Whole Blood</h2>
</header>
<div class="row gtr-150">
<div class="col-4 col-12-medium">
<!-- Sidebar -->
<section id="sidebar">
<section>
<h3 style="color:black">What is Cancer?</h3>
<figure>
<a href="https://doi.org/10.1016/j.jsamd.2019.01.006" class="image fit">
<img src="images/Rostami et al.png" alt="Schematic of Metastasis and CTCC microenvironment." />
</a>
<figcaption style="color:black">
Figure 2: (a) Tumor cells are shed from a primary tumor into the bloodstream as single CTCs or rarer CTCCs which can lead to the development of a secondary tumor. (b) CTCCs are composed of a heterogeneous mixture of CTCs and other cells commonly found in the bloodstream. This figure was created by <a href="https://doi.org/10.1016/j.jsamd.2019.01.006"><i> Rostami et al.</i> (2019)</a> and adapted for use here<sup>2</sup>.
</figcaption>
</figure>
<br>
<p style="color:black"> Cancer is a rare occurance under which some cells within the body grow uncontrollably into a clump of cells (tumor) before spreading to other parts of the body, forming a secondary tumor in a process known as metastasis<sup>2</sup>.
During the normal cell cycle, old or damaged cells die and are replaced by healthy, new cells. However, this process can sometimes fail, leading to these cells continuing to grow past normal restrictors of growth becoming cancerous<sup>2</sup>. To learn more click below to visit the National Cancer Insititue website.
</p>
<footer>
<ul class="actions">
<li><a href="https://www.cancer.gov/about-cancer/understanding/what-is-cancer" class="button1" style="color:black">Learn More</a></li>
</ul>
</footer>
</section>
<hr />
<section>
<h3 style="color:black">What is Metastasis and why should we care?</h3>
<figure>
<a href="https://seer.cancer.gov" class="image fit"><img src="images/SEERData.png" alt="Cancer statistics from SEER database" /></a>
<figcaption style="color:black">
Figure 3: Five-year survival rates for the three most common types of cancer in the USA as they grow from a local, to a regional, to a distant (metastatic) state. Values acquired from the National Cancer Institute Surveillance, Epidemiology, and End Results <a href="https://seer.cancer.gov">(SEER)</a> Program<sup>3</sup>.
</figcaption>
</figure>
<br>
<p style="color:black"> During tumor growth, single circulating tumor cells (CTCs) and aggregates of circulating tumor cells called circulating tumor cell clusters (CTCCs) will be shed into the bloodstream (Figure 2)<sup>4</sup>.
These CTCs and CTCCs can escape into distant organs, forming a metastatic tumor. As the healthy cells compete with metastatic tumor cells for nutrients, the function of essential organs and systems can be impacted, leading to death.
Examining the five-year survival rates for patients with the three most common types of cancers in the US, metastatic growth signifcantly reduces a patients long-term survival (Figure 3)<sup>3</sup>.
To learn more about metastasis click below.
</p>
<footer>
<ul class="actions">
<li><a href="https://www.cancer.gov/types/metastatic-cancer" class="button1">Learn More </a></li>
</ul>
</footer>
</section>
</section>
</div>
<div class="col-8 col-12-medium imp-medium">
<!-- Content -->
<section id="content">
<h3 style="color:black">What is Back-scatter Flow Cytometry?</h3>
<figure>
<a href="https://www.nature.com/articles/s41598-022-14003-5" class="image fit">
<img src="images/FlowSystem.png.webp" alt="Summary of experimental system for CTCC detection." />
</a>
<figcaption style="color:black">
Figure 1: (a) A microfluidic channel with whole blood flowing through it. (b) Schematic of the back-scatter flow cytometer (BSFC). D:dichroic, L:lens, M:mirror, BP:bandpass filter, BS:beam splitter, PMT:photomultiplier tube, Pol:polarizer, CAM:CCD camera, ND:neutral density filter, Cyl Lens:cylindrical lens.
(c) Schematic of experimental design. Blood is collected from mice and spiked with CTCCs before being flowed through a 30x30 μm<sup>2</sup> channel. Figure is reproduced from <a href="https://www.nature.com/articles/s41598-022-14003-5"> <i>Vora et al.</i> (2022)</a><sup>1</sup>.
</figure>
<br>
<p style="color:black">
Flow Cytometry is a light-based interrogation method to analyze rare small cellular events in liquid samples. Liquid is pulled into a small channel, often only wide enough for a single cell to pass through. A laser beam is focused through the tube at a orthogonally. As cells cross the laser beam, light scattering in the foward and side directions are collected by
specialized detectors called photomultiplier tubes (PMTs). PMTs are specilized low-light detectors that can convert photons into electrical signals that can be registered on a computer. In addition to collecting scattered light signals, specialized markers are used to tag various cellular events in order to distinguish various cell types. These tags are known as fluorescence
stains which are attached to specific cells using targetted proteins. Fluorescence is a chemical process under which light is absorbed by the protein marker and then emitted back out as a red-shifted color. Specilized filters can be set up to specifically detect these colors in order to distinguish different cells based on their "glow". Currently, flow cytometry is limited to
<i>in vitro</i> use, this means samples must be collected from a patient or animal and then processed outside of the body. <a href="https://doi.org/10.1364/ol.29.000077"><i> Novak et al.</i> (2004)</a> and <a href="https://doi.org/10.1158/0008-5472.can-04-1058"><i> Georgakoudi et al.</i> (2004)</a> first explored the principles of flow cytometry for <i>in vivo</i> detection of
rare circulating tumor cell clusters (CTCCs)<sup>5,6</sup>.
</p>
<p style="color:black">
Back scatter flow cytometry (BSFC) is based on the initial innovations by <a href="https://doi.org/10.1364/ol.29.000077"><i> Novak et al.</i> (2004)</a> and <a href="https://doi.org/10.1158/0008-5472.can-04-1058"><i> Georgakoudi et al.</i> (2004)</a>. Unlike conventional flow cytometry, BSFC collects light scattered back in the same direction as the illumination beam.
We utilize three wavelengths - a 405 nm, a 488 nm, and a 633 nm laser - to irradiate our sample. Angled illumination is used in order to block light reflected from the glass slide (Figure 1b). A confocal slit is placed to block out of focus light from reaching the detectors. In addition to collecting scattered light signal, we also collect fluorescence signals from a green
fluorescence tag and natural red fluorescence from the cells. The green tag is a useful ground truth label for CTCC identification. A series of specialized mirrors are used to isolate signals from different sources. For greater detail, see <a href="https://www.nature.com/articles/s41598-022-14003-5"> <i>Vora et al.</i> (2022)</a>. To learn more about IVFC and
our BSFC system, click below.
</p>
<footer>
<ul class="actions">
<li><a href="https://sites.tufts.edu/georgakoudilab/monitoring-of-circulating-cells-in-vivo-or-within-microfluidic-devices-using-flow-cytometry/" class="button1">Learn More </a></li>
</ul>
</footer>
<h3 style="color:black">Application of Machine Learning to BSFC Data</h3>
<p style="color:black">
As a tumor grows, individual cells from the tumor will shed from the primary site into the bloodstream<sup>4</sup>. These individual tumor cells are referred to as circulating tumor cells (CTCs). CTCs occur at a rate of 1-75 CTCs per 7.5 mL of blood while CTCCs occur at an even lower rate of less than 4 CTCCs per 7.5 mL of blood in metastatic cancer patients<sup>4</sup>. While rare,
CTCCs are 23-50 times more likely to lead to metastatic growth compared to individual CTCs<sup>1</sup>. <i>In vitro</i> detection methods have been widely used to detect CTCCs but can over or under estimate the presence of CTCCs leading to poor correlation with prognosis<sup>1</sup>. <i>In vivo</i> detection could improve correlation with prognosis with continous monitoring of CTCCs
in the blood of patients however, current <i>in vivo</i> flow cytometry (IVFC) is limited by the need for staining of cancer cells or limited application to melanoma (skin cancer)<sup>1</sup>. We propose a new method of label-free detection of CTCCs in whole blood using light scattering. Using a focused illumination slit, we can estimate the size of cellular events as they cross a
5 μm illuimation slit. Larger cell clusters will feature broader peaks in the collected time-series data which single cell events will feature narrow peak widths. Using a threshold, we can seperate CTCC events from non-CTCC (NC) events, however, while efficient, blood scatter and immune cell response leads to poor signal-to-noise ratio (SNR) and detection of a larger number of false positive
events. For successful use of IVFC, it is not only important to be sensitive to CTCC presence but also to be precise in our detection. As such, we decided to explore machine learning techniques for time-series classification of CTCCs in low-SNR scattering datasets.
</p>
</section>
</div>
</div>
<h3 style="color:black">References</h3>
<ol>
<li style="color:black">Vora, N. et al. Label-free flow cytometry of rare circulating tumor cell clusters in whole blood. Sci Rep 12, 10721 (2022). <a href="https://doi.org/10.1038/s41598-022-14003-5">https://doi.org/10.1038/s41598-022-14003-5</a></li>
<li style="color:black">What Is Cancer?. National Cancer Institute. <a href="https://www.cancer.gov/about-cancer/understanding/what-is-cancer">https://www.cancer.gov/about-cancer/understanding/what-is-cancer</a>. Accessed 12 November 2022.</li>
<li style="color:black">Howlader, N. et al. SEER Cancer Statistics Review, 1975–2017. Bethesda, MD. <a href="https://seer.cancer.gov/csr/1975_2017/">https://seer.cancer.gov/csr/1975_2017/</a>. Accessed 15 May 2021.</li>
<li style="color:black">Rostami, P. et al. Novel approaches in cancer management with circulating tumor cell clusters. J. Sci. Adv. Mater. Devices 4, 1–18 (2019). <a href="https://doi.org/10.1016/j.jsamd.2019.01.006">https://doi.org/10.1016/j.jsamd.2019.01.006</a></li>
<li style="color:black">Novak, P. et al. In vivo flow cytometer for real-time detection and quantification of circulating cells. Opt Lett. 2004 Jan 1;29(1):77-9.<a href="https://doi.org/10.1364/ol.29.000077">https://doi.org/10.1364/ol.29.000077</a>.</li>
<li style="color:black">Georgakoudi, I. et al. In Vivo Flow Cytometry: A New Method for Enumerating Circulating Cancer Cells. Cancer Res (2004) 64 (15): 5044–5047. <a href="https://doi.org/10.1158/0008-5472.CAN-04-1058">https://doi.org/10.1158/0008-5472.CAN-04-1058</a>.</li>
</ol>
</div>
</div>
<!-- Footer -->
<footer id="footer">
<ul class="icons">
<li><a href="https://www.linkedin.com/in/nilayvora/" class="icon brands alt fa-linkedin-in"><span class="label">LinkedIn</span></a></li>
<li><a href="https://github.com/nilayvphd" class="icon brands alt fa-github"><span class="label">GitHub</span></a></li>
<li><a href="https://gitlab.tufts.edu/nvora01" class="icon brands alt fa-gitlab"><span class="label">GitLab</span></a></li>
<li><a href="https://scholar.google.com/citations?user=WOHFGOQAAAAJ&hl=en&oi=ao" class="icon brands alt fa-google"><span class="label">Google Scholar</span></a></li>
<li><a href="mailto:nilay.vora@tufts.edu" class="icon solid alt fa-envelope"><span class="label">Email</span></a></li>
</ul>
<ul class="copyright">
<li>© Nilay Vora. All rights reserved.</li><li>Design: <a href="http://html5up.net">HTML5 UP</a></li>
</ul>
</footer>
</div>
<!-- Scripts -->
<script src="assets/js/jquery.min.js"></script>
<script src="assets/js/jquery.scrolly.min.js"></script>
<script src="assets/js/jquery.dropotron.min.js"></script>
<script src="assets/js/jquery.scrollex.min.js"></script>
<script src="assets/js/browser.min.js"></script>
<script src="assets/js/breakpoints.min.js"></script>
<script src="assets/js/util.js"></script>
<script src="assets/js/main.js"></script>
</body>
</html>